

Wednesday, October 23, 2024

Volume 55 No. 10



NOTICE – Items in this issue will be listed online weekly and printed monthly.

ABSCI CORP

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues	2,168	4,636
Cost & expenses	45,587	65,107
Deprec., depl. & amort.		7,002
Operating income	(50,219)	(67,473)
Interest expense		577
Other income (expense), net	3,832	3,041
Net before taxes	(46,713)	(65,009)
Income taxes	12	18
Net income	(46,725)	(65,027)
Balance for common		(65,027)
Earnings common share		
Primary	\$(0.44)	\$(0.71)
Fully Diluted	\$(0.44)	\$(0.71)
Common Shares:		
Full Diluted	106,164	91,655
Year-end	113,444	92,591

ACUMEN PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Cost & expenses	42,155	26,613
Operating income	(42,155)	(26,613)
Interest income		3,716
Other income (expense), net	(122)	(20)
Gains or losses	1,050	
Net income	(35,410)	(22,917)
Earnings common share		
Primary	\$(0.59)	\$(0.56)
Fully Diluted	\$(0.59)	\$(0.56)
Common Shares:		
Full Diluted	59,946	41,025
Year-end	60,080	41,025

ADICET BIO INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Cost & expenses	63,719	68,211
Operating income	(63,719)	(68,211)
Interest income		5,279
Interest expense		23
Other income (expense), net	(113)	(329)
Net income	(57,917)	(63,284)
Balance for common		(63,284)
Earnings common share		
Primary	\$(0.68)	\$(1.47)
Fully Diluted	\$(0.68)	\$(1.47)
Common Shares:		
Full Diluted	84,848	42,957
Year-end	82,401	43,066

ADMA BIOLOGICS INC

Earnings, 6 mos. to Jun 30 (Consol. – \$):		
	2024	2023
Total Revenues	189,066,000	117,036,725
Cost & expenses	127,709,000	117,965,444
Operating income	61,022,000	(1,286,395)
Interest income		581,275
Interest expense		12,414,591
Other income (expense), net	(51,000)	(39,811)
Net before taxes	54,252,000	
Income taxes	4,384,000	
Net income	49,868,000	(13,159,522)
Balance for common		(13,159,522)
Earnings common share		
Primary	\$0.22	\$(0.06)
Fully Diluted	\$0.21	\$(0.06)

Common Shares:		
Full Diluted	239,645,940	222,304,676
Year-end	233,026,736	224,526,748

ADVERUM BIOTECHNOLOGIES INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues		3,600
Cost & expenses	47,721	66,904
Operating income	(47,721)	(63,304)
Other income (expense), net	4,458	2,776
Net before taxes	(60,528)	
Income taxes		38
Net income	(43,263)	(60,566)
Balance for common		(60,566)
Earnings common share		
Primary	\$(2.31)	\$(6.00)
Fully Diluted	\$(2.31)	\$(6.00)
Common Shares:		
Full Diluted	18,713	10,054
Year-end	20,801	10,099

AKEBIA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30 (Consol. – \$):		
	2024	2023
Total Revenues	76,255,000	96,381,000
Cost & expenses	99,915,000	130,975,000
Operating income	(23,660,000)	(34,594,000)
Interest expense		3,204,000
Other income (expense), net	(461,000)	(252,000)
Gains or losses	2,201,000	
Net income	(26,567,000)	(38,050,000)
Balance for common		(38,050,000)
Earnings common share		
Primary	\$(0.13)	\$(0.20)
Fully Diluted	\$(0.13)	\$(0.20)
Common Shares:		
Full Diluted	207,330,274	185,798,865
Year-end	209,929,145	188,128,869

ALLOGENE THERAPEUTICS INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues	22	52
Cost & expenses	140,957	179,684
Operating income	(140,935)	(179,632)
Other income (expense), net	(131,358)	(179,200)
Net income	(272,293)	(358,832)
Earnings common share		
Primary	\$(0.73)	\$(1.23)
Fully Diluted	\$(0.73)	\$(1.23)
Common Shares:		
Full Diluted	179,578	145,686
Year-end	209,049	167,134

ALLOVIR INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Cost & expenses	40,071	90,535
Operating income	(40,071)	(90,535)
Interest income		2,841
Other income (expense), net	1,090	1,244
Net income	(36,375)	(86,450)
Earnings common share		
Primary	\$(0.32)	\$(0.92)
Fully Diluted	\$(0.32)	\$(0.92)
Common Shares:		
Full Diluted	114,909	93,968
Year-end	115,312	113,716

AMKOR TECHNOLOGY INC.

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues	2,826,985	
Net Sales		2,929,461
Cost & expenses	2,672,332	2,784,436
Operating income	154,653	145,025
Other income (expense), net	115	(205)
Foreign currency		(6,812)
Net before taxes	153,552	129,939
Income taxes	26,508	20,271
Net income	127,044	109,668
Balance for common		109,637
Earnings common share		
Primary	\$0.51	\$0.45
Fully Diluted	\$0.51	\$0.44
Common Shares:		
Full Diluted	247,790	247,046
Year-end	246,302	245,689

ANAPTYSBIO INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues	18,150	4,834
Cost & expenses	100,672	89,378
Operating income	(82,522)	(84,544)
Interest income		9,139
Other income (expense), net	(2)	(1)
Net before taxes	(90,587)	
Income taxes	9	
Net income	(90,596)	(84,100)
Balance for common		(84,100)
Earnings common share		
Primary	\$(3.35)	\$(3.08)
Fully Diluted	\$(3.35)	\$(3.08)
Common Shares:		
Full Diluted	27,079	27,288
Year-end	27,434	26,531

ANDERSONS INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Total Revenues	5,513,422	
Cost & expenses	5,445,703	7,862,004
Operating income	71,314	39,417
Other income (expense), net	8,334	
Net before taxes	71,314	39,417
Income taxes	6,179	15,848
Net income	65,135	23,569
Earnings common share		
Primary	\$1.22	\$1.20
Fully Diluted	\$1.21	\$1.18
Common Shares:		
Full Diluted	34,302	34,193
Year-end	34,069	33,794

ANNEXON INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2024	2023
Cost & expenses	62,152	77,998
Operating income	(62,152)	(78,933)
Interest income		5,069
Net income	(54,786)	(73,864)
Earnings common share		
Primary	\$(0.43)	\$(0.99)
Fully Diluted	\$(0.43)	\$(0.99)
Common Shares:		
Full Diluted	126,403	74,547
Year-end	105,540	53,151

APYX MEDICAL CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	22,393	25,711
Net Sales		25,711
Cost & expenses	34,555	32,557
Operating income	(12,162)	(6,846)
Interest income	230	777
Interest expense		641
Other income (expense), net	(22)	(22)
Net before taxes	(14,073)	(6,752)
Income taxes	103	(2,201)
Net income	(14,176)	(4,551)
Balance for common		(4,477)
Earnings common share		
Primary	\$(0.41)	\$(0.13)
Fully Diluted	\$(0.41)	\$(0.13)
Common Shares:		
Full Diluted	34,644	34,600
Year-end	34,644	34,629

ARCTURUS THERAPEUTICS HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	87,871	90,804
Cost & expenses	139,409	131,423
Operating income	(51,538)	(40,619)
Interest income		6,472
Other income (expense), net	33,953	33,953
Net before taxes	(43,815)	(1,116)
Income taxes	218	680
Net income	(44,033)	(1,796)
Earnings common share		
Primary	\$(1.64)	\$(0.07)
Fully Diluted	\$(1.64)	\$(0.07)
Common Shares:		
Full Diluted	26,923	26,557
Year-end	27,042	26,574

ARCUTIS BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	80,427	7,971
Cost & expenses	162,126	150,999
Operating income	(81,699)	(143,028)
Interest expense		14,391
Other income (expense), net	9,273	6,328
Net before taxes	(87,390)	
Income taxes	324	
Net income	(87,714)	(151,091)
Balance for common		(151,091)
Earnings common share		
Primary	\$(0.75)	\$(2.46)
Fully Diluted	\$(0.75)	\$(2.46)
Common Shares:		
Full Diluted	117,265	61,301
Year-end	116,480	61,630

ARHAUS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	604,963	617,467
Cost & expenses	557,221	518,022
Operating income	47,742	99,445
Other income (expense), net	197	660
Net before taxes	49,977	100,756
Income taxes	12,644	26,474
Net income	37,333	74,282
Earnings common share		
Primary	\$0.27	\$0.53
Fully Diluted	\$0.27	\$0.53
Common Shares:		
Full Diluted	140,736	139,960
Year-end	140,461	

ATHIRA PHARMA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Cost & expenses	55,715	61,410
Operating income	(55,715)	(61,410)
Other income (expense), net	2,519	3,993
Net income	(53,196)	(57,417)
Balance for common		(57,417)
Earnings common share		

Primary	\$(1.39)	\$(1.51)
Fully Diluted	\$(1.39)	\$(1.51)
Common Shares:		
Full Diluted	38,351	37,962
Year-end	38,439	38,055

AVEPOINT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2024	2023
Total Revenues	152,495,000	124,441,000
Cost & expenses	157,834,000	140,357,000
Operating income	(5,339,000)	(15,916,000)
Other income (expense), net	(3,566,000)	(1,111,000)
Net before taxes	(8,905,000)	(16,416,000)
Income taxes	5,987,000	5,291,000
Net income	(14,892,000)	(21,707,000)
Earnings common share		
Primary	\$(0.08)	\$(0.12)
Fully Diluted	\$(0.08)	\$(0.12)
Common Shares:		
Full Diluted	182,150,000	183,068,000
Year-end	186,657,000	185,723,000

AXT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	50,611	38,000
Net Sales		38,000
Cost & expenses	55,843	49,282
Operating income	(5,232)	(11,282)
Other income (expense), net	3,011	3,034
Net before taxes	(2,852)	(9,010)
Income taxes	395	9
Net income	(3,247)	(9,019)
Balance for common	(3,687)	(8,525)
Earnings common share		
Primary	\$(0.09)	\$(0.20)
Fully Diluted	\$(0.09)	\$(0.20)
Common Shares:		
Full Diluted	43,039	42,542
Year-end	44,482	43,657

BACKBLAZE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	61,253	47,983
Net Sales		47,983
Cost & expenses	81,572	78,697
Operating income	(20,319)	(30,714)
Interest expense	1,865	1,865
Gains or losses		1,129
Net before taxes	(21,395)	
Income taxes	6	
Net income	(21,401)	(31,450)
Earnings common share		
Primary	\$(0.52)	\$(0.91)
Fully Diluted	\$(0.52)	\$(0.91)
Common Shares:		
Full Diluted	41,189	34,539
Year-end	42,886	35,985

BARRETT BUSINESS SERVICES, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	545,433	519,297
Cost & expenses	525,960	495,741
Operating income	15,709	20,150
Interest expense		38
Other income (expense), net	6,436	55
Gains or losses		4,444
Net before taxes	22,057	24,611
Income taxes	5,492	6,776
Net income	16,565	17,835
Earnings common share		
Primary	\$0.63	\$0.66
Fully Diluted	\$0.62	\$0.64
Common Shares:		
Full Diluted	26,794	27,724
Year-end	25,949	26,744

BEL FUSE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

Primary	\$(1.39)	\$(1.51)
Fully Diluted	\$(1.39)	\$(1.51)
Common Shares:		
Full Diluted	38,351	37,962
Year-end	38,439	38,055

	2024	2023
Total Revenues	261,295,000	
Net Sales		341,121,000
Cost & expenses	220,818,000	294,124,000
Operating income	40,477,000	46,997,000
Interest expense		1,890,000
Other income (expense), net	1,346,000	(190,000)
Gains or losses		1,115,000
Net before taxes	43,235,000	46,032,000
Income taxes	8,555,000	3,685,000
Net income	34,680,000	42,347,000
Balance for common		40,600,000
Earnings common share		
Primary	\$2.73	\$3.17
Fully Diluted	\$2.73	\$3.17
Common Shares:		
Full Diluted	12,682,000	2,142,000
Year-end	12,574,458	12,779,349

BEYOND MEAT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/29/24	07/01/23
Total Revenues	168,788	194,385
Net Sales		194,385
Cost & expenses	256,193	305,860
Operating income	(87,405)	(111,475)
Interest expense		1,978
Other income (expense), net	600	4,654
Equity earnings	23	3,738
Net before taxes	(88,849)	(108,799)
Income taxes	(32)	5
Net income	(88,840)	(112,542)
Balance for common		(112,542)
Earnings common share		
Primary	\$(1.37)	\$(1.76)
Fully Diluted	\$(1.37)	\$(1.76)
Common Shares:		
Full Diluted	64,797	64,119
Year-end	64,993	64,318

BIORA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2024	2023
Total Revenues	860	4
Net Sales		4
Cost & expenses	32,162	30,482
Operating income	(31,302)	(30,478)
Interest expense		5,383
Other income (expense), net	10,109	(86)
Gains or losses	26,918	703
Net before taxes	2,257	(35,244)
Income taxes	(19)	4
Net income	2,276	(35,248)
Balance for common		(35,248)
Earnings common share		
Primary	\$0.07	\$(3.01)
Fully Diluted	\$(0.06)	\$(3.01)
Common Shares:		
Full Diluted	69,282	11,718
Year-end	35,943	13,421

BIOVENTUS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/29/24	07/01/23
Total Revenues	280,674	
Net Sales		256,128
Cost & expenses	300,896	337,013
Operating income	(24,041)	(85,308)
Interest expense		20,281
Other income (expense), net	(222)	1,075
Net before taxes	(44,526)	(104,514)
Income taxes	(6,432)	235
Income contin. oper.		(104,749)
Net income	(38,094)	(179,178)
Earnings common share		
Primary	\$(0.45)	\$(2.29)
Fully Diluted	\$(0.45)	\$(2.29)
Common Shares:		
Full Diluted	63,720	62,338
Year-end	65,172	78,591

BJ'S RESTAURANTS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	07/02/24	07/04/23
Total Revenues	687,261,000	690,950,000
Net Sales		690,950,000
Cost & expenses	629,746,000	642,802,000
Deprec., depl. & amort.		35,320,000
Operating income	21,479,000	12,828,000
Interest expense		2,229,000
Other income (expense), net	3,468,000	818,000
Net before taxes	22,277,000	11,417,000
Income taxes	(2,603,000)	(3,996,000)
Net income	24,880,000	15,413,000
Earnings common share		
Primary	\$1.07	\$0.66
Fully Diluted	\$1.04	\$0.64
Common Shares:		
Full Diluted	23,954,000	23,961,000
Year-end	23,138,000	23,544,000

BLADE AIR MOBILITY INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	106,260,000	106,260,000
Net Sales		106,260,000
Cost & expenses	141,476,000	131,296,000
Operating income	(22,017,000)	(25,036,000)
Interest income		4,031,000
Other income (expense), net		(1,896,000)
Gains or losses	2,565,000	
Invest. income		(95,000)
Net before taxes	(15,592,000)	(22,996,000)
Income taxes	(32,000)	(572,000)
Net income	(15,560,000)	(22,424,000)
Balance for common		(22,424,000)
Earnings common share		
Primary	\$(0.20)	\$(0.31)
Fully Diluted	\$(0.20)	\$(0.31)
Common Shares:		
Full Diluted	76,700,008	72,584,138
Year-end	77,934,085	73,169,003

BLUM HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	5,569,000	4,146,000
Cost & expenses	15,572,000	11,242,000
Operating income	(10,003,000)	(7,096,000)
Other income (expense), net	15,691,000	2,990,000
Gains or losses	(483,000)	
Invest. income		(61,000)
Net before taxes	4,078,000	(4,461,000)
Income contin. oper.	3,764,000	(4,994,000)
Net income	20,313,000	(2,838,000)
Earnings common share		
Primary	\$2.32	\$(0.59)
Fully Diluted	\$1.92	\$(0.59)
Common Shares:		
Full Diluted	10,811,340	8,516,196
Year-end	9,744,914	

BRIDGEBIO PHARMA INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	213,288	3,467
Cost & expenses	388,484	275,729
Operating income	(175,196)	(272,262)
Interest income		8,667
Interest expense		40,715
Other income (expense), net	(25,664)	875
Gains or losses	126,294	
Net income	(111,704)	(303,435)
Earnings common share		
Primary	\$(0.59)	\$(1.90)
Fully Diluted	\$(0.59)	\$(1.90)
Common Shares:		
Full Diluted	183,146	156,646
Year-end	188,033	161,420

BRUKER CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	1,522,400,000	1,367,200,000
Cost & expenses	1,409,500,000	1,158,300,000
Operating income	112,900,000	208,900,000
Other income (expense), net	(19,600,000)	

Equity earnings		(900,000)
Net before taxes	95,500,000	184,100,000
Income taxes	35,900,000	49,800,000
Net income	59,600,000	135,200,000
Earnings common share		
Primary	\$0.40	\$0.91
Fully Diluted	\$0.40	\$0.91
Common Shares:		
Full Diluted	147,000,000	147,600,000
Year-end	151,391,821	146,817,075

CADIZ INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	1,634	939
Net Sales		939
Cost & expenses	12,891	10,041
Operating income	(11,857)	(9,736)
Other income (expense), net	(274)	(5,551)
Net before taxes	(15,717)	(17,751)
Income taxes	5	4
Net income	(15,722)	(17,755)
Balance for common	(18,275)	(20,308)
Earnings common share		
Primary	\$(0.27)	\$(0.31)
Fully Diluted	\$(0.27)	\$(0.31)
Common Shares:		
Full Diluted	67,384	64,633
Year-end	67,800	66,596

CARLYLE SECURED LENDING INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues		118,440
Cost & expenses	64,949	28,368
Operating income	55,322	54,918
Other income (expense), net	6,993	
Gains or losses	683	
Invest. income	(14,988)	
Net before taxes		54,918
Income taxes		1,173
Net income	48,010	53,745
Balance for common	46,260	
Earnings common share		
Primary	\$0.91	\$1.02
Fully Diluted	\$0.85	\$1.02
Common Shares:		
Full Diluted	56,366	56,274
Year-end	50,795	50,795

CDW CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Net Sales		10,729,200
Cost & expenses	9,535,000	9,961,700
Operating income	761,100	767,500
Interest expense		115,900
Other income (expense), net	(1,200)	(1,900)
Net before taxes	656,300	649,700
Income taxes	159,100	157,000
Net income	497,200	492,700
Earnings common share		
Primary	\$3.70	\$3.65
Fully Diluted	\$3.66	\$3.60
Common Shares:		
Full Diluted	135,800	136,700
Year-end	133,600	134,000

CLOVER HEALTH INVESTMENTS CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	703,182,000	642,130,000
Cost & expenses	718,050,000	749,432,000
Operating income	(15,516,000)	108,580,000
Gains or losses		(484,000)
Income contin. oper.	(16,000,000)	108,587,000
Net income	(11,762,000)	101,420,000
Earnings common share		
Primary	\$(0.03)	\$(0.23)
Fully Diluted	\$(0.03)	\$(0.23)
Common Shares:		
Full Diluted	487,575,520	479,819,237
Year-end	481,561,408	

COMMERCIAL VEHICLE GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues		524,903
Net Sales		524,903
Cost & expenses	454,642	494,315
Operating income	7,332	30,588
Interest expense		5,694
Other income (expense), net	(419)	(105)
Net before taxes	2,174	24,789
Income taxes	836	5,949
Net income	1,338	18,840
Earnings common share		
Primary	\$0.04	\$0.57
Fully Diluted	\$0.04	\$0.57
Common Shares:		
Full Diluted	33,834	33,312
Year-end	31,305	31,081

COMSCORE INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	172,632	185,242
Net Sales		185,242
Cost & expenses	174,836	232,836
Operating income	(3,805)	(51,206)
Interest expense		715
Other income (expense), net	(18)	(203)
Gains or losses	669	
Foreign currency		(1,634)
Net before taxes	(3,455)	(53,758)
Income taxes	(693)	(178)
Net income	(2,762)	(53,580)
Balance for common	(11,246)	(61,277)
Earnings common share		
Primary	\$(2.28)	\$(13.00)
Fully Diluted	\$(2.28)	\$(13.00)
Common Shares:		
Full Diluted	4,938	4,735
Year-end	4,890	4,754

CONDUIT PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Cost & expenses	6,095,000	913,672
Operating income	(6,095,000)	25,850
Other income (expense), net	(2,613,000)	
Net before taxes		25,850
Income taxes		249,292
Net income	(8,935,000)	(223,442)
Earnings common share		
Primary	\$(0.12)	\$(0.03)
Fully Diluted	\$(0.12)	\$(0.03)
Common Shares:		
Full Diluted	73,840,488	7,650,504
Year-end	74,000,234	6,247,978

CONIFER HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues		49,502
Cost & expenses	52,045	53,065
Operating income	(3,865)	(3,563)
Equity earnings		(286)
Net before taxes	(3,865)	
Income taxes	(18)	
Net income	(3,561)	(3,738)
Balance for common	(3,876)	
Earnings common share		
Primary	\$(0.32)	\$(0.31)
Fully Diluted	\$(0.32)	\$(0.31)
Common Shares:		
Full Diluted	12,223	12,218
Year-end	12,223	12,223

CONSTRUCTION PARTNERS INC

Earnings, 9 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	1,285,726	1,088,522
Cost & expenses	1,220,254	1,051,405
Operating income	65,472	37,117
Interest expense		13,801
Other income (expense), net	47	925
Net before taxes	52,532	24,241

Income taxes	12,905	6,153
Net income	39,627	18,088
Earnings common share		
Primary	\$0.76	\$0.35
Fully Diluted	\$0.75	\$0.35
Common Shares:		
Full Diluted	52,572	52,114
Year-end	52,762	52,727

CORBUS PHARMACEUTICALS HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):	2024	2023
Cost & expenses	20,611,000	25,486,016
Operating income	(20,611,000)	(25,486,016)
Other income (expense), net	3,604,000	412,164
Gains or losses	39,000	
Foreign currency		(1,193)
Net income	(16,896,000)	(26,528,653)
Earnings common share		
Primary	\$(1.75)	\$(6.27)
Fully Diluted	\$(1.75)	\$(6.27)
Common Shares:		
Full Diluted	9,681,875	4,229,894
Year-end	11,498,917	4,422,741

CREDITRISKMONITOR.COM, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):	2024	2023
Total Revenues	9,742,474	9,273,243
Net Sales		9,273,243
Cost & expenses	9,609,897	8,466,351
Deprec., depl. & amort.	192,087	
Operating income	(61,486)	614,805
Other income (expense), net	397,495	333,547
Net before taxes	336,009	948,352
Income taxes	79,416	221,721
Net income	256,593	726,631
Balance for common		726,631
Earnings common share		
Primary	\$0.02	\$0.07
Fully Diluted	\$0.02	\$0.07
Common Shares:		
Full Diluted	10,761,722	10,802,176
Year-end	10,722,401	10,722,401

CUMBERLAND PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):	2024	2023
Total Revenues	18,346,550	20,113,515
Net Sales		20,113,515
Cost & expenses	19,031,970	19,234,015
Operating income	(2,895,938)	(1,508,819)
Interest income	107,251	
Interest expense		378,988
Other income (expense), net		2,828,871
Net before taxes	(2,982,224)	1,048,315
Income taxes	22,885	13,875
Net income	(3,005,109)	1,034,440
Balance for common		1,064,384
Earnings common share		
Primary	\$(0.21)	\$0.07
Fully Diluted	\$(0.21)	\$0.07
Common Shares:		
Full Diluted	14,107,852	14,570,798
Year-end	14,083,183	14,330,990

CYTMX THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2024	2023
Total Revenues	66,578	48,223
Cost & expenses	63,373	57,224
Operating income	3,205	(4,398)
Interest income		4,635
Other income (expense), net	(12)	(32)
Net before taxes	7,358	
Income taxes	101	
Net income	7,257	(4,398)
Earnings common share		
Primary	\$0.09	\$(0.07)
Fully Diluted	\$0.09	\$(0.07)
Common Shares:		
Full Diluted	84,116	66,393
Year-end	78,118	66,768

DISTRIBUTION SOLUTIONS GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2024	2023
Total Revenues	855,622	726,254
Net Sales		726,254
Cost & expenses	838,681	695,757
Operating income	16,941	30,497
Interest expense		17,162
Other income (expense), net	97	(1,757)
Gains or losses	(3)	
Net before taxes	(7,585)	11,578
Income taxes	(4,257)	2,647
Net income	(3,328)	8,931
Earnings common share		
Primary	\$(0.07)	\$0.42
Fully Diluted	\$(0.07)	\$0.41
Common Shares:		
Full Diluted	46,798	21,653
Year-end	46,787	23,350

DIXIE GROUP INC.

Earnings, 6 mos. to (Consol. - \$000):	06/29/24	07/01/23
Total Revenues	135,761	
Net Sales		141,093
Cost & expenses	134,324	140,533
Operating income	1,437	560
Other income (expense), net	(8)	10
Net before taxes	(1,723)	(3,137)
Income taxes	20	34
Income contin. oper.	(1,743)	(3,171)
Net income	(1,891)	(3,484)
Earnings common share		
Primary	\$(0.13)	\$(0.24)
Fully Diluted	\$(0.13)	\$(0.24)
Common Shares:		
Full Diluted	14,872	14,742
Year-end	15,587	15,556

DRILLING TOOLS INTERNATIONAL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):	2024	2023
Total Revenues	74,507,000	
Cost & expenses	56,095,000	52,736,000
Operating income	7,365,000	16,239,000
Other income (expense), net	(2,798,000)	(6,035,000)
Gains or losses	771,000	455,000
Net before taxes	4,346,000	9,737,000
Income taxes	854,000	3,099,000
Net income	3,492,000	6,638,000
Balance for common		6,324,000
Earnings common share		
Primary	\$0.12	\$0.21
Fully Diluted	\$0.12	\$0.21
Common Shares:		
Full Diluted	30,321,002	29,768,568
Year-end	29,859,564	29,768,568

DRIVEN BRANDS HOLDINGS INC

Earnings, 6 mos. to (Consol. - \$000):	06/29/24	07/01/23
Total Revenues	1,183,792	1,169,318
Cost & expenses	956,905	910,922
Operating income	58,455	174,779
Interest expense		79,012
Foreign currency		2,977
Net before taxes	58,455	98,744
Income taxes	24,035	31,246
Net income	34,420	67,498
Balance for common		66,078
Earnings common share		
Primary	\$0.21	\$0.41
Fully Diluted	\$0.21	\$0.40
Common Shares:		
Full Diluted	160,683	166,882
Year-end	164,082	167,367

EASTERN CO.

Earnings, 6 mos. to (Consol. - \$):	06/29/24	07/01/23
Total Revenues	141,080,976	140,833,158
Net Sales		140,833,158
Cost & expenses	132,371,514	136,246,598
Operating income	8,709,462	4,586,560

Interest expense		1,507,110
Other income (expense), net	(9,712)	(378,520)
Net before taxes	7,024,781	2,700,930
Income taxes	1,569,336	694,409
Net income	5,455,445	2,006,521
Balance for common		2,006,521
Earnings common share		
Primary	\$0.88	\$0.32
Fully Diluted	\$0.87	\$0.32
Common Shares:		
Full Diluted	6,250,222	6,227,873
Year-end	6,228,432	6,238,316

ELEVATION ONCOLOGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2024	2023
Cost & expenses	20,832	26,579
Operating income	(20,832)	(26,579)
Other income (expense), net	(942)	(580)
Net before taxes	(21,146)	(27,159)
Income taxes	22	10
Net income	(21,168)	(27,169)
Earnings common share		
Primary	\$(0.38)	\$(1.06)
Fully Diluted	\$(0.38)	\$(1.06)
Common Shares:		
Full Diluted	55,415	25,608
Year-end	54,654	42,382

EMPIRE PETROLEUM CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):	2024	2023
Total Revenues	22,185,483	19,762,427
Cost & expenses	24,341,825	22,953,116
Deprec., depl. & amort.		1,333,531
Operating income	(6,323,453)	(4,524,220)
Interest expense		422,186
Other income (expense), net	(991,245)	21,906
Net income	(8,364,967)	(4,924,500)
Earnings common share		
Primary	\$(0.30)	\$(0.22)
Fully Diluted	\$(0.30)	\$(0.22)
Common Shares:		
Full Diluted	27,752,816	22,101,264
Year-end	31,375,375	22,124,592

EVERSPIN TECHNOLOGIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2024	2023
Total Revenues	25,066	30,593
Cost & expenses	28,485	28,274
Operating income	(3,419)	2,319
Other income (expense), net	791	2,390
Net before taxes	(2,628)	
Income taxes	76	
Net income	(2,704)	4,646
Earnings common share		
Primary	\$(0.13)	\$0.23
Fully Diluted	\$(0.13)	\$0.22
Common Shares:		
Full Diluted	21,410	21,068
Year-end	21,657	20,743

EXELON CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2024	2023
Total Revenues	11,403,000	10,380,000
Cost & expenses	7,604,000	6,844,000
Deprec., depl. & amort.		1,727,000
Operating income	2,026,000	1,809,000
Other income (expense), net	139,000	249,000
Net before taxes	1,215,000	1,218,000
Income taxes	109,000	
Net income	1,106,000	1,012,000
Balance for common		1,012,000
Earnings common share		
Primary	\$1.11	\$1.00
Fully Diluted	\$1.10	\$0.99
Common Shares:		
Full Diluted	1,001,000	996,000
Year-end	1,000,000	995,219

FIRSTHAND TECHNOLOGY VALUE FUND INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	322,938	322,938
Cost & expenses	(2,574,660)	828,130
Operating income	2,636,661	2,636,661
Other income (expense), net	(2,879,112)	(2,879,112)
Net income	(242,451)	(505,192)
Earnings common share		
Primary	\$(0.04)	\$(0.07)
Fully Diluted	\$(0.04)	\$(0.07)
Common Shares:		
Full Diluted	6,893,056	6,893,056
Year-end	6,893,056	6,893,056

	2024	2023	2022
Total number of employees	1,500	1,700	1,800
Number of common stockholders	3,000	3,000	250
Total Revenue	412,752,000	393,692,000	544,282,000
Other expense	...	(347,000)	...
Net income	...	14,778,000	...
(Gain) on disposal of assets	3,262,000
Diluted EPS
Excluding ExtraOrd Items	\$1.91

Other liabilities	791,000	577,000
Total liabilities	124,095,000	148,929,000
Common stock	8,407,000	...
Common stock	...	8,292,000
Additional paid-in capital	39,573,000	36,605,000
Treasury stock, at cost; 132 shares and 0 shares as of 30, 2020 and 2019, respectively	71,731,000	...
Treasury stock, at cost	...	70,072,000
Retained earnings	174,118,000	...
Retained earnings (accumulated deficit)	...	166,796,000
Total shareholders' equity (deficit)	150,367,000	141,621,000
Total Equity	150,367,000	...

FLEXSTEEL INDUSTRIES, INC.

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

	2024	2023	2022
Net Sales	412,752,000	393,692,000	544,282,000
Net sales	...	393,692,000	544,282,000
COST OF GOODS SOLD	25,508,000	322,745,000	471,602,000
Cost of goods sold	...	322,745,000	471,602,000
Gross margin (loss)	87,244,000	70,947,000	72,680,000
Selling, general & administrative expenses	70,444,000	62,846,000	66,733,000
Restructuring expense	2,982,000	...	730,000
Gain (loss) on disposal of assets	1,400,000
Environmental remediation	...	(2,788,000)	...
Operating income (loss)	17,080,000	10,542,000	6,617,000
Other income (expense)	20,000	18,000	121,000
Interest expense	1,550,000	1,341,000	835,000
Total other income (expense)	(1,530,000)	(1,323,000)	(714,000)
Income (loss) before income taxes - U.S.	...	6,680,000	2,151,000
Income (loss) before income taxes - outside the U.S.	...	2,539,000	3,752,000
Income (loss) before income taxes	15,550,000	9,219,000	5,903,000
Current federal income tax provision (benefit)	4,708,000	799,000	2,966,000
Current state & other income tax provision (benefit)	1,084,000
Deferred	(1,454,000)	(7,154,000)	...
State and other - current	1,768,000	796,000	...
Net Income After Taxes	10,528,000
Income tax provision (benefit)	5,022,000	(5,559,000)	4,050,000
Net income (loss)	10,528,000	14,778,000	1,853,000
Weighted average shares outstanding - basic	5,170,000	5,225,000	6,329,000
Weighted average shares outstanding - diluted	5,519,000	5,385,000	6,503,000
Year end shares outstanding	5,200,000	5,174,000	5,300,000
Earnings (loss) per share - before acctg change - basic	\$2.04
Net earnings (loss) per share - basic	\$2.04	\$2.83	\$0.29
Net earnings (loss) per share - diluted	\$1.91	\$2.74	\$0.28
Common DPS - by Period End Date - Gross	\$0.60
Cash dividends declared per common share	...	\$0.60	...
Full-Time Employees (Period End)	1,500

□ Approximately

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2024	2023
Cash and cash equivalents	4,761,000	...
Cash & cash equivalents	...	3,365,000
Trade receivables, gross	46,678,000	40,768,000
Less: allowances for doubtful accounts	2,440,000	2,600,000
Trade receivables less allowance for doubtful accounts	44,238,000	...
Trade receivables	...	38,168,000
Raw materials	14,030,000	18,616,000
Work in process & finished parts	2,654,000	3,741,000
Finished goods	79,893,000	99,719,000
Inventories	96,577,000	...
Inventories	...	122,076,000
Other current assets	8,098,000	6,417,000
Assets held for sale	1,707,000	616,000
Total current assets	155,381,000	170,642,000
Land	3,226,000	3,457,000
Buildings & improvements	41,968,000	49,131,000
Machinery & equipment	20,864,000	19,824,000
Delivery equipment	2,570,000	2,962,000
Computer software & hardware	3,226,000	3,558,000
Construction in progress	1,439,000	4,231,000
Computer software and hardware	10,033,000	8,919,000
Total property, plant & equipment	83,326,000	92,082,000
accumulated depreciation	46,617,000	...
Less accumulated depreciation	...	53,430,000
Property, plant and equipment, net	36,709,000	...
Property, plant & equipment, net	...	38,652,000
Operating lease right-of-use assets	61,439,000	68,294,000
Notes receivable	...	3,865,000
Deferred income taxes	8,607,000	7,154,000
Cash value of life insurance	...	1,063,000
Other assets	879,000	880,000
VAT receivable	11,447,000	...
Total assets	274,462,000	290,550,000
Accounts payable - trade	25,830,000	24,745,000
Current portion of operating lease liabilities	7,517,000	7,179,000
Accrued payroll & related items	12,059,000	9,955,000
Accrued insurance	...	1,920,000
Accrued advertising	...	5,358,000
Accrued income taxes	362,000	...
Other accrued liabilities	1,900,000	5,948,000
Warranty	1,017,000	1,057,000
Sales and advertising related items	6,073,000	...
Other	7,027,000	...
Dividends	973,000	...
Dividends	...	988,000
Total current liabilities	60,406,000	55,105,000
Operating lease liabilities, less current maturities	58,076,000	64,974,000
Long-term debt	...	28,273,000
Lines of credit	4,822,000	...

Recent Dividends:

1. Flexsteel Industries, Inc. common.

ExDate	Amt	Declared	Record	Payable
12/22/2020	0.10	12/09/2020	12/23/2020	01/04/2021
03/16/2021	0.15	03/03/2021	03/17/2021	03/29/2021
06/29/2021	0.15	06/15/2021	06/30/2021	07/12/2021
09/21/2021	0.15	09/08/2021	09/22/2021	10/04/2021
12/21/2021	0.15	12/07/2021	12/22/2021	01/03/2022
03/22/2022	0.15	03/08/2022	03/23/2022	04/04/2022
06/28/2022	0.15	06/14/2022	06/29/2022	07/11/2022
09/27/2022	0.15	09/13/2022	09/28/2022	10/10/2022
12/27/2022	0.15	12/13/2022	12/28/2022	01/09/2023
03/21/2023	0.15	03/07/2023	03/22/2023	04/03/2023
06/27/2023	0.15	06/13/2023	06/28/2023	07/10/2023
09/26/2023	0.15	09/12/2023	09/27/2023	10/09/2023
12/27/2023	0.15	12/12/2023	12/28/2023	01/08/2024
03/25/2024	0.15	03/05/2024	03/26/2024	04/04/2024
06/26/2024	0.15	06/11/2024	06/26/2024	07/08/2024
09/25/2024	0.17	09/10/2024	09/25/2024	10/07/2024

Annual Dividends:

1. Flexsteel Industries, Inc. common.

2021	0.55	2022	0.60	2023	0.60
2024	0.62				

FREIGHTCAR AMERICA INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2024	2023
Total Revenues	308,474	169,595
Net Sales	...	169,595
Cost & expenses	291,430	160,772
Operating income	17,044	8,823
Other income (expense), net	(739)	(21,127)
Gains or losses	(15,541)	...
Net before taxes	(3,474)	(23,255)
Income taxes	(80)	671
Net income	(3,394)	(23,926)
Balance for common	...	(23,926)
Earnings common share		
Primary	\$(0.11)	\$(0.93)
Fully Diluted	\$(0.11)	\$(0.93)
Common Shares:		
Full Diluted	30,236	27,552
Year-end	18,874	17,899

FRMO CORP.

Annual Report

Consolidated Income Statement, Years Ended May 31 (\$):

	2024	2023	2022
Fees	4,678,025
Board fees	5,044,368	1,614,213	...
Dividends and interest income, net	3,763,818
Dividends & interest income, net	...	5,081,547	1,645,601
Net realized gains (losses) from investments	510,909	(1,035,096)	(1,504,448)
Unrealized gains (losses) from digital assets	6,272,047

				Consolidated Balance Sheet, Years Ended May 31 (\$):			
				2024		2023	
Equity earnings (losses) from limited partnerships & limited liability companies	653,378	Cash and cash equivalents	39,189,906
Unrealized gains (losses) from investments	53,935,183	(13,661,130)	(5,576,320)	Cash & cash equivalents	...	38,077,492	...
Total revenue before unrealized gains (losses) from equity securities	(103,764)	Accounts receivable (due from related parties)	3,443,834
Unrealized gains (losses) from equity securities	66,186,297	(28,368,182)	13,977,730	Accounts receivable (due from related parties)	...	3,214,132	...
Fees and other income	2,714,862	Prepaid income taxes	640,623	158,004	...
Fees and other income	...	3,221,561	...	Bond & equity securities, available for sale, at fair value	221,681,671
Total revenue	138,427,484	(33,147,087)	13,873,966	Equity securities, available for sale, at fair value	...	159,728,999	...
General & administrative expenses	...	1,497,408	1,081,545	Equity securities, at fair value	10,978,796
Depreciation	248,140	Other current assets	167,357	167,297	...
Depreciation	...	339,720	298,942	Total current assets	276,102,187	201,345,924	...
General and administrative expenses	1,307,685	Cryptocurrency mining - Accumulated Depreciation & Impairment	1,286,317	1,050,854	...
Total expenses	...	1,837,128	1,380,487	Cryptocurrency mining assets, gross	2,426,289	2,381,608	...
Income (loss) from operations before provision for income taxes	136,871,659	(34,984,215)	12,493,479	Investments in limited partnerships & other equity investments at fair value	127,578,968	70,656,050	...
Current federal income taxes	361,697	629,327	(235,050)	Investment in securities exchanges	6,463,351	4,869,070	...
Current state & city income taxes	394,524	614,727	(235,030)	Other investments	469,430	484,409	...
Total current income taxes	756,221	1,244,054	(470,080)	Investment in Horizon Kinetics LLC	17,204,752	14,607,525	...
Deferred federal income taxes (provisions)	17,570,047	(4,446,793)	(261,302)	Participation in Horizon Kinetics LLC Revenue	...	10,200,000	10,200,000
Deferred state & city income taxes	94,140	(19,704)	(42,258)	Stream	10,200,000	10,200,000	...
Total deferred income taxes	17,664,187	(4,466,497)	(303,560)	Total assets	439,158,660	303,493,732	...
Net Income (Loss)	118,451,251	Accounts payable & accrued expenses	589,228	322,631	...
Provision for (benefit from) income taxes	18,420,408	(3,222,443)	(773,640)	Redeemable preferred stock	950,762	2,352,910	...
Net income (loss)	118,451,251	(31,761,772)	13,267,119	Current portion of mortgage note payable	...	668,624	31,215
Less net income (loss) attributable to noncontrolling interests	(45,892,580)	19,157,800	(10,321,242)	Securities sold, not yet purchased (proceeds of \$10,670,820 and)	668,624	31,215	...
Net income (loss) attributable to the company	72,558,671	(12,603,972)	2,945,877	Total current liabilities	2,208,614	2,706,756	...
Weighted average shares outstanding - basic	44,022,781	44,021,069	44,016,014	Deferred tax liability	33,668,129
Weighted average shares outstanding - diluted	44,026,529	44,021,069	44,034,813	Deferred tax liability	...	16,003,942	...
Year end shares outstanding	44,022,781	44,022,781	44,017,781	Mortgage note payable, net of current portion	...	668,625	...
Net income (loss) per share - basic	\$1.65	\$(0.29)	\$0.07	Total liabilities	35,876,743	19,379,323	...
Net income (loss) per share - diluted	\$1.65	\$(0.29)	\$0.07	Common Stock	44,022
Number of shareholders	58	Common stock	...	44,022	...
Net (Loss) Income Attributable to the Company NET (LOSS) INCOME PER COMMON SHARE	...	(12,603,972)	...	Additional paid-in capital	42,050,118	41,754,855	...
Basic EPS Excluding ExtraOrdinary Items	\$1.65	\$(0.29)	...	Retained earnings	200,042,552
Diluted EPS Excluding ExtraOrd Items	\$1.65	\$(0.29)	...	Retained earnings (accumulated deficit)	...	127,483,881	...
				Stockholders' equity attributable to the company	242,136,692	169,282,758	...
				Noncontrolling interests	161,145,225	114,831,651	...
				Total stockholders' equity (deficit)	403,281,917	284,114,409	...
				Recent Dividends:			
				1. FRMO Corp. series R preferred.			
				No dividends paid.			
				2. FRMO Corp. common.			
				No dividends paid.			
				Annual Dividends:			
				1. FRMO Corp. series R preferred.			
				No dividends paid.			
				2. FRMO Corp. common.			
				No dividends paid.			
				FRMO CORP.			
				Earnings, 3 mos. to Aug 31(Consol. - \$):			
					2024	2023	
				Total Revenues	111,162,365	89,125,442	
				Cost & expenses	368,962	288,910	
				Operating income	110,744,283	88,762,947	
				Net before taxes	110,744,283	88,762,947	
				Income taxes	...	8,293,618	
				Net income	100,255,428	80,469,329	
				Earnings common share			
				Primary	\$0.78	\$0.73	
				Fully Diluted	\$0.78	\$0.73	
				Common Shares:			
				Full Diluted	44,027,112	44,030,469	
				Year-end	44,022,781	44,022,781	
				Consolidated Balance Sheet Items, as of (\$):			
				Assets:		2024	
				Cash & equivalents	42,471,912	42,471,912	
				Current assets	366,046,992	366,046,992	
				Net property & equip.	1,071,078	1,071,078	
				Total assets	548,341,607	548,341,607	
				Liabilities:			
				Current liabilities	2,864,934	2,864,934	
				Stockholders' equity	276,567,890	276,567,890	
				Net current assets	363,182,058	363,182,058	
				FRONTIER COMMUNICATIONS PARENT INC			
				Earnings, 6 mos. to Jun 30(Consol. - \$000):			
					2024	2023	
				Total Revenues	2,942,000	2,889,000	
				Net Sales	2,889,000	2,889,000	
				Cost & expenses	1,975,000	1,947,000	
				Operating income	181,000	258,000	
				Other income (expense), net	88,000	(4,000)	
				Net before taxes	(129,000)	2,000	
				Income taxes	(7,000)	1,000	
				Net income	(122,000)	1,000	
				Balance for common	1,000	1,000	
				Earnings common share			
				Primary	\$(0.49)	\$0.00	
				Fully Diluted	\$(0.49)	\$0.00	
				Common Shares:			
				Full Diluted	247,382	246,517	
				Year-end	248,962	245,744	
				FTC SOLAR INC			
				Earnings, 6 mos. to Jun 30(Consol. - \$000):			
					2024	2023	
				Total Revenues	24,017	73,253	
				Net Sales	73,253	73,253	
				Cost & expenses	48,443	96,017	
				Operating income	(24,426)	(22,764)	
				Interest expense	86	86	
				Other income (expense), net	29	(215)	
				Gains or losses	3,574	898	
				Net before taxes	(20,958)	(22,167)	
				Income taxes	54	9	
				Net income	(21,012)	(22,176)	
				Balance for common	(22,176)	(22,176)	
				Earnings common share			
				Primary	\$(0.17)	\$(0.20)	
				Fully Diluted	\$(0.17)	\$(0.20)	
				Common Shares:			
				Full Diluted	125,816	109,632	
				Year-end	127,003	118,118	
				GITLAB INC			
				Earnings, 6 mos. to Jul 31(Consol. - \$000):			
					2024	2023	
				Total Revenues	351,771	266,459	
				Net Sales	233,287	233,287	
				Cost & expenses	446,416	378,749	
				Operating income	(94,645)	(112,290)	
				Interest income	16,427	16,427	
				Other income (expense), net	235	(83)	
				Equity earnings	1,665	1,665	
				Foreign currency	(994)	(994)	
				Net before taxes	(69,323)	(98,605)	
				Income taxes	(26,710)	(26,710)	
				Net income	(42,613)	(104,107)	
				Earnings common share			
				Primary	\$(0.26)	\$(0.67)	
				Fully Diluted	\$(0.26)	\$(0.67)	
				Common Shares:			
				Full Diluted	158,973	152,683	
				Year-end	160,425	154,610	
				GLYCOMMETICS INC			
				Earnings, 6 mos. to Jun 30(Consol. - \$):			

	2024	2023
Cost & expenses	21,472,721	19,870,963
Operating income	(21,472,721)	(19,870,963)
Interest income		1,252,701
Net income	(20,832,073)	(18,618,262)
Earnings common share		
Primary	\$(0.32)	\$(0.30)
Fully Diluted	\$(0.32)	\$(0.30)
Common Shares:		
Full Diluted	64,470,541	62,313,155
Year-end	64,483,958	64,313,333

GOHEALTH INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	291,470	325,937
Cost & expenses	289,084	337,673
Operating income	(44,642)	(58,765)
Interest expense		34,156
Other income (expense), net	(82)	32
Net before taxes	(80,771)	(92,889)
Income taxes	(111)	(117)
Net income	(80,660)	(92,772)
Balance for common	(37,011)	(39,904)
Earnings common share		
Primary	\$(3.76)	\$(4.41)
Fully Diluted	\$(3.76)	\$(4.41)
Common Shares:		
Full Diluted	9,844	9,044
Year-end	10,058	22,236

GOODYEAR TIRE & RUBBER CO.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	9,107,000	9,808,000
Net Sales		9,808,000
Cost & expenses	8,793,000	10,057,000
Operating income	88,000	(372,000)
Interest income		34,000
Other income (expense), net		(116,000)
Gains or losses		62,000
Foreign currency		(41,000)
Net before taxes	88,000	(310,000)
Income taxes	66,000	(3,000)
Net income	22,000	(307,000)
Balance for common		(309,000)
Earnings common share		
Primary	\$0.10	\$(1.08)
Fully Diluted	\$0.10	\$(1.08)
Common Shares:		
Full Diluted	288,000	285,000
Year-end	284,687	283,452

GOSSAMER BIO INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Cost & expenses	85,714	94,242
Operating income	10,128	(94,242)
Interest income		1,282
Interest expense		6,929
Other income (expense), net	5,563	8,228
Net before taxes	11,739	
Income taxes	4,435	
Net income	7,304	(91,661)
Balance for common		(91,661)
Earnings common share		
Primary	\$0.03	\$(0.96)
Fully Diluted	\$0.03	\$(0.96)
Common Shares:		
Full Diluted	225,978	95,160
Year-end	226,227	95,453

GULF ISLAND FABRICATION, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	84,143	101,494
Net Sales		101,494
Cost & expenses	77,152	100,417
Operating income	6,991	1,077
Net before taxes	8,136	1,737
Income taxes	7	
Net income	8,129	1,743
Balance for common		1,743
Earnings common share		

Primary	\$0.50	\$0.11
Fully Diluted	\$0.48	\$0.11
Common Shares:		
Full Diluted	16,810	16,098
Year-end	16,516	16,287

HEALTHQUITY INC**Earnings, 6 mos. to Jul 31(Consol. – \$000):**

	2024	2023
Total Revenues	587,525	487,981
Cost & expenses	430,440	393,728
Operating income	100,559	47,921
Other income (expense), net	(466)	502
Net before taxes	79,855	24,236
Income taxes	15,220	9,561
Net income	64,635	14,675
Earnings common share		
Primary	\$0.74	\$0.17
Fully Diluted	\$0.73	\$0.17
Common Shares:		
Full Diluted	88,606	86,356
Year-end	87,324	

HILLMAN SOLUTIONS CORP**Earnings, 6 mos. to (Consol. – \$):**

	06/29/24	07/01/23
Total Revenues	729,737,000	
Cost & expenses	240,603,000	225,177,000
Operating income	15,674,000	(14,266,000)
Net before taxes	15,674,000	(14,266,000)
Income taxes	4,631,000	(9,679,000)
Net income	11,043,000	(4,587,000)
Earnings common share		
Primary	\$0.06	\$(0.02)
Fully Diluted	\$0.06	\$(0.02)
Common Shares:		
Full Diluted	198,037,000	194,596,000
Year-end	196,156,159	194,707,000

HONEST CO INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	179,266	167,933
Net Sales		167,933
Cost & expenses	184,625	199,977
Operating income	(5,359)	(32,044)
Other income (expense), net		29
Net before taxes	(5,441)	(32,242)
Income taxes	38	40
Net income	(5,479)	(32,282)
Balance for common		(32,282)
Earnings common share		
Primary	\$(0.06)	\$(0.34)
Fully Diluted	\$(0.06)	\$(0.34)
Common Shares:		
Full Diluted	97,676	93,607
Year-end	100,157	95,061

HUDSON GLOBAL INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	69,603	87,969
Net Sales		87,969
Cost & expenses	72,146	85,894
Operating income	(3,227)	1,373
Other income (expense), net	(134)	83
Net before taxes	(3,174)	1,650
Income taxes	165	718
Net income	(3,339)	932
Balance for common		932
Earnings common share		
Primary	\$(1.10)	\$0.30
Fully Diluted	\$(1.10)	\$0.30
Common Shares:		
Full Diluted	3,026	3,130
Year-end	2,751	2,823

HUMACYTE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2024	2023
Cost & expenses	56,077,000	49,243,000
Operating income	(56,077,000)	(49,243,000)
Interest income		2,954,000
Interest expense		3,409,000

Other income (expense), net	(9,977,000)
Gains or losses	(30,492,000)
Net income	(88,559,000)
Earnings common share	
Primary	\$(0.78)
Fully Diluted	\$(0.78)
Common Shares:	
Full Diluted	113,710,344
Year-end	119,347,688

HYPERFINE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2024	2023
Total Revenues	6,926,000	6,016,000
Net Sales		6,016,000
Cost & expenses	28,422,000	30,743,000
Operating income	(21,496,000)	(24,727,000)
Other income (expense), net	21,000	31,000
Net income	(20,004,000)	(22,797,000)
Balance for common		(22,797,000)
Earnings common share		
Primary	\$(0.28)	\$(0.32)
Fully Diluted	\$(0.28)	\$(0.32)
Common Shares:		
Full Diluted	71,987,688	71,033,629
Year-end	72,186,990	71,339,826

IDEAYA BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues		11,424
Cost & expenses	115,944	70,412
Operating income	(115,944)	(58,988)
Net income	(92,344)	(51,566)
Earnings common share		
Primary	\$(1.21)	\$(0.99)
Fully Diluted	\$(1.21)	\$(0.99)
Common Shares:		
Full Diluted	76,536	52,332
Year-end	76,091	57,440

IDENTIV INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	13,399	20,365
Cost & expenses	25,182	27,175
Operating income	(12,304)	(6,888)
Net before taxes	(12,304)	(6,888)
Income taxes	1	2
Income contin. oper.	(12,305)	(6,890)
Net income	(10,774)	(3,863)
Balance for common	(11,255)	(4,491)
Earnings common share		
Primary	\$(0.48)	\$(0.20)
Fully Diluted	\$(0.48)	\$(0.20)
Common Shares:		
Full Diluted	23,413	22,924
Year-end	23,448	23,112

IHEARTMEDIA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2024	2023
Total Revenues	1,728,130	1,731,253
Net Sales		1,731,253
Cost & expenses	2,462,987	2,460,732
Deprec., depl. & amort.		216,577
Operating income	(944,375)	(946,056)
Other income (expense), net	(833)	27,152
Gains or losses		(12,543)
Invest. income	91,582	
Net before taxes	(1,044,718)	(1,125,597)
Income taxes		(20,252)
Net income	(1,000,097)	(1,105,345)
Balance for common		(1,106,730)
Earnings common share		
Primary	\$(6.65)	\$(7.44)
Fully Diluted	\$(6.65)	\$(7.44)
Common Shares:		
Full Diluted	150,466	148,774
Year-end	146,732	144,477

IKENA ONCOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2024	2023
Total Revenues	7,316,000	41,321,000
Cost & expenses	34,049,000	41,321,000
Operating income	(34,049,000)	(34,005,000)
Other income (expense), net	228,000	(6,000)
Gains or losses		2,677,000
Invest. income	4,034,000	
Net before taxes	(29,787,000)	
Income taxes	89,000	
Net income	(29,876,000)	(31,334,000)
Balance for common		(31,334,000)
Earnings common share		
Primary	\$(0.62)	\$(0.83)
Fully Diluted	\$(0.62)	\$(0.83)
Common Shares:		
Full Diluted	48,258,111	37,783,486
Year-end	48,258,111	42,299,478

IMMUNITYBIO INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	1,087	401
Cost & expenses	195,616	197,126
Operating income	(194,529)	(196,725)
Interest income		876
Interest expense		62,051
Other income (expense), net	4,020	9,404
Gains or losses	(2,647)	(6,294)
Invest. income	(45)	(6)
Net income	(268,714)	(254,796)
Earnings common share		
Primary	\$(0.40)	\$(0.59)
Fully Diluted	\$(0.40)	\$(0.59)
Common Shares:		
Full Diluted	679,885	432,944
Year-end	691,793	440,674

INTERNATIONAL ISOTOPES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	6,073,691	
Cost & expenses	6,520,011	6,577,732
Operating income	(446,320)	(376,032)
Interest income		28,942
Interest expense		165,196
Other income (expense), net	155,376	100,930
Net income	(387,496)	(411,356)
Earnings common share		
Common Shares:		
Full Diluted	521,473,413	516,746,718
Year-end	522,957,618	517,941,366

INTUITIVE SURGICAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2024	2023
Total Revenues	5,938,600	5,195,800
Cost & expenses	4,324,600	3,879,200
Operating income	1,614,000	1,316,600
Net before taxes	1,864,000	1,443,000
Income taxes	214,500	236,400
Net income	1,649,500	1,206,600
Earnings common share		
Primary	\$4.61	\$3.40
Fully Diluted	\$4.53	\$3.34
Common Shares:		
Full Diluted	361,400	357,100
Year-end	356,200	352,000

JACK HENRY & ASSOCIATES, INC.

Annual Report

Consolidated Income Statement, Years Ended Jun. 30

(\$000):

	2024	2023	2022
Hardware revenue	2,215,543		
Revenue	2,215,543	2,077,702	1,942,884
Cost of revenue		1,219,062	1,128,614
Research & development expenses	148,256	142,678	121,355
Selling, general & administrative expenses	278,419	235,274	218,296
Total expenses	1,726,152	1,597,014	1,468,265

Operating income	489,391	480,688	474,619	Leasehold improvements	51,432	51,125
Interest Income	25,012			Equipment & furniture	418,853	394,507
Interest income		8,959	32	Aircraft & equipment	44,140	41,400
Interest Expense	16,384			Construction in progress	12,298	14,208
Interest expense		15,073	2,384	Finance lease right of use asset		312
Total interest income (expense)		(6,114)	(2,352)	Property & equipment, gross	701,237	
Income (loss) before income taxes	498,019	474,574	472,267	Accumulated depreciation	486,168	
Current provision (benefit) for income taxes - federal	93,890	125,622	59,390	Less accumulated depreciation		466,711
Current provision (benefit) for income taxes - state	23,222	30,505	18,089	Property and Equipment, net	215,069	
Deferred provision (benefit) for income taxes - federal	(1,615)	(40,218)	24,391	Property & equipment, net		205,664
Deferred provision (benefit) for income taxes - state	706	(7,981)	7,481	Non-current deferred costs	183,307	161,465
Reported Net Income After Tax	381,816			Computer Software, net of amortization	592,761	
Provision (benefit) for income taxes	116,203	107,928	109,351	Computer software, net of amortization		565,714
Net income (loss)	381,816	366,646	362,916	Other non-current assets	417,621	322,698
Weighted average shares outstanding - basic	72,867	72,918	73,324	Customer relationships, net of amortization	56,757	
Weighted average shares outstanding - diluted	73,025	73,096	73,486	Other intangible assets, net of amortization		65,528
Year end shares outstanding	72,872	72,894	72,879	Goodwill	804,797	804,797
Income (loss) per share - continuing operations - basic	\$5.24			Other intangible assets, net of amortization		19,998
Net income (loss) per share - basic	\$5.24	\$5.03	\$4.95	Total assets	2,924,481	2,773,826
Income (loss) per share - continuing operations - diluted	\$5.23			Accounts payable	25,314	19,156
Net income (loss) per share - diluted	\$5.23	\$5.02	\$4.94	Accrued acquisition costs	192,316	
Common DPS - by Period End Date - Gross	\$2.14			Accrued expenses	200,770	172,629
Dividends declared per share		\$2.02	\$1.90	Long-term debt, current maturities	90,000	
Number of full time employees	7,170	7,120	6,847	Deferred revenues	317,730	
Number of common stockholders	344,699	311,805	271,813	Other-broker-dealer operations		331,974
Cost of Revenue	1,299,477			Operating Lease Liabilities - Current	8,454	
NET INCOME		366,646		Total current liabilities	633,814	523,759
Total Interest Income (Expense)	8,628			Notes payable, less current portion	60,000	
Total number of employees	7,170			Non-current deferred revenues	71,202	67,755
				Deferred income tax liability	243,522	244,431
				Debt, net of current maturities		275,000
				Other long-term liabilities	73,579	54,371
				Deferred Tax - Credit - Liability	301,801	
				Deferred Tax - Debit - Liability	(58,279)	
				Total long-term liabilities	448,303	641,557
				Total liabilities	1,082,117	1,165,316
				Common stock	1,042	
				Common stock		1,041
				Additional paid-in capital	619,805	583,836
				Retained earnings		2,855,751
				Treasury stock at cost	1,860,173	
				Less treasury stock at cost		1,832,118
				Total stockholders' equity	1,842,364	1,608,510
				Rep Total Equity & Minority Interest	1,842,364	

□ As is; □ Approximately; □ As of August 15, 2022

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2024	2023
Cash & cash equivalents	38,284	12,243
Receivables, gross	340,510	369,207
Less: allowance for credit losses	7,477	7,955
Receivables, net	333,033	
Receivables, net		361,252
Income tax receivable	6,149	7,523
Prepaid cost of product	168,768	
Deferred costs	85,784	77,766
Prepaid expenses and other		169,178
Total current assets	632,018	627,962
Land	16,357	16,581
Land improvements	24,322	24,251
Buildings	133,835	129,991

Recent Dividends:

1. Jack Henry & Associates, Inc. common.

ExDate	Amt	Declared	Record	Payable
03/05/2021	0.46	02/16/2021	03/08/2021	03/25/2021
05/27/2021	0.46	05/17/2021	05/28/2021	06/14/2021
09/08/2021	0.46	08/23/2021	09/09/2021	09/29/2021
12/02/2021	0.46	11/17/2021	12/03/2021	12/23/2021
03/07/2022	0.49	02/14/2022	03/08/2022	03/25/2022
05/26/2022	0.49	05/16/2022	05/27/2022	06/14/2022
09/08/2022	0.49	08/22/2022	09/09/2022	09/29/2022

11/30/2022	0.49	11/16/2022	12/01/2022	12/22/2022
03/07/2023	0.52	02/13/2023	03/08/2023	03/24/2023
05/25/2023	0.52	05/15/2023	05/26/2023	06/15/2023
09/07/2023	0.52	08/21/2023	09/08/2023	09/28/2023
11/30/2023	0.52	11/15/2023	12/01/2023	12/22/2023
03/07/2024	0.55	02/12/2024	03/08/2024	03/26/2024
05/24/2024	0.55	05/09/2024	05/28/2024	06/17/2024
09/06/2024	0.55	08/26/2024	09/06/2024	09/27/2024

Annual Dividends:

1. Jack Henry & Associates, Inc. common.

2021	1.84	2022	1.96	2023	2.08
2024	1.65				

JAKKS PACIFIC INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	238,695,000	274,417,000
Net Sales	274,417,000	
Cost & expenses	252,196,000	262,174,000
Operating income	(13,681,000)	12,048,000
Interest income		203,000
Interest expense		4,305,000
Other income (expense), net	210,000	(6,987,000)
Net before taxes	(13,406,000)	959,000
Income taxes	(4,447,000)	95,000
Net income	(8,959,000)	864,000
Balance for common	(7,909,000)	402,000
Earnings common share		
Primary	\$(0.75)	\$0.04
Fully Diluted	\$(0.75)	\$0.04
Common Shares:		
Full Diluted	10,577,000	10,428,000
Year-end	10,800,892	9,870,927

KLX ENERGY SERVICES HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	354,900	473,600
Net Sales	473,600	
Cost & expenses	321,600	401,000
Operating income	(11,700)	38,500
Interest expense		17,800
Net before taxes	(29,800)	20,700
Income taxes	400	(100)
Net income	(30,200)	20,800
Balance for common		20,800
Earnings common share		
Primary	\$(1.86)	\$1.38
Fully Diluted	\$(1.86)	\$1.37
Common Shares:		
Full Diluted	16,200	15,200
Year-end	16,800	16,400

KNIGHTSCOPE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	5,457,000	6,460,000
Cost & expenses	20,498,000	18,926,000
Operating income	(15,041,000)	(12,466,000)
Other income (expense), net	(80,000)	(137,000)
Gains or losses	1,451,000	5,815,000
Net income	(13,863,000)	(7,242,000)
Balance for common		(7,242,000)
Earnings common share		
Primary	\$(0.13)	\$(7.00)
Fully Diluted	\$(0.13)	\$(7.00)
Common Shares:		
Full Diluted	106,099,552	1,001,741
Year-end	133,693,155	1,477,538

KODIAK SCIENCES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Cost & expenses	94,038	159,447
Operating income	(94,038)	(159,447)
Interest income		8,300
Interest expense		8
Other income (expense), net	(425)	187
Net income	(88,156)	(150,968)
Balance for common		(150,968)
Earnings common share		
Primary	\$(1.68)	\$(2.88)
Fully Diluted	\$(1.68)	\$(2.88)

Common Shares:		
Full Diluted	52,532	52,358
Year-end	52,615	52,453

LEAP THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Cost & expenses	36,077	57,388
Operating income	(36,077)	(57,388)
Interest income		2,005
Other income (expense), net	499	582
Foreign currency		(452)
Net income	(33,948)	(55,253)
Balance for common	(34,182)	(55,253)
Earnings common share		
Primary	\$(1.01)	\$(4.01)
Fully Diluted	\$(1.01)	\$(4.01)
Common Shares:		
Full Diluted	33,830	13,795
Year-end	38,264	25,565

LIFETIME BRANDS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	283,908	
Net Sales	291,871	
Cost & expenses	280,911	289,281
Operating income	2,997	2,590
Other income (expense), net	(14,152)	1,483
Gains or losses	(256)	
Equity earnings	2,092	8,640
Net before taxes	(22,182)	(6,791)
Income taxes	153	(106)
Net income	(24,427)	(15,325)
Earnings common share		
Primary	\$(1.14)	\$(0.72)
Fully Diluted	\$(1.14)	\$(0.72)
Common Shares:		
Full Diluted	21,399	21,174
Year-end	22,158	21,814

LIFEWAY FOODS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	93,791,000	77,134,000
Net Sales	77,134,000	
Cost & expenses	84,571,000	70,661,000
Operating income	8,950,000	6,203,000
Interest expense		213,000
Other income (expense), net	15,000	
Gains or losses		33,000
Net before taxes	8,867,000	6,023,000
Income taxes	2,658,000	2,037,000
Net income	6,209,000	3,986,000
Earnings common share		
Primary	\$0.42	\$0.27
Fully Diluted	\$0.41	\$0.26
Common Shares:		
Full Diluted	15,176,000	15,058,000
Year-end	14,791,000	14,656,000

LOVESAC CO

Earnings, 6 mos. to (Consol. - \$):

	08/04/24	07/30/23
Total Revenues	289,233,000	295,722,000
Net Sales	295,722,000	
Cost & expenses	308,202,000	296,585,000
Operating income	(26,227,000)	(6,699,000)
Net before taxes	(24,789,000)	(6,007,000)
Income taxes	(5,968,000)	(1,257,000)
Net income	(18,821,000)	(4,750,000)
Earnings common share		
Primary	\$(1.21)	\$(0.31)
Fully Diluted	\$(1.21)	\$(0.31)
Common Shares:		
Full Diluted	15,564,016	15,326,702
Year-end	15,558,682	15,481,925

MADRIGAL PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	14,638,000	
Cost & expenses	329,213,000	164,786,000
Operating income	(314,575,000)	164,786,000

Interest income		7,327,000
Interest expense		5,237,000
Net income	(299,512,000)	162,696,000

Earnings common share		
Primary	\$(14.47)	\$(8.91)
Fully Diluted	\$(14.47)	\$(8.91)
Common Shares:		
Full Diluted	20,702,041	18,249,778
Year-end	21,700,893	18,459,033

MARKER THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	2,413,297	1,996,995
Cost & expenses	7,270,380	10,440,536
Operating income	(4,857,083)	(8,443,541)
Interest income		119,734
Net income	(4,585,499)	(2,451,787)
Earnings common share		
Primary	\$(0.51)	\$(0.28)
Fully Diluted	\$(0.51)	\$(0.28)
Common Shares:		
Full Diluted	8,910,097	8,760,209
Year-end	8,900,000	8,800,000

MATTEL INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	1,889,237	1,901,743
Net Sales		1,901,743
Cost & expenses	1,841,548	1,954,006
Operating income	47,689	(52,263)
Other income (expense), net	(11,721)	3,586
Equity earnings	(11,381)	(7,747)
Net before taxes	5,604	(99,607)
Income taxes	(11,594)	(12,575)
Net income	28,579	(79,285)
Balance for common		(79,285)
Earnings common share		
Primary	\$0.08	\$(0.22)
Fully Diluted	\$0.08	\$(0.22)
Common Shares:		
Full Diluted	347,359	354,748
Year-end	339,900	354,000

MOLECULAR TEMPLATES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	11,658	43,494
Cost & expenses	20,004	43,452
Operating income	(8,346)	42
Other income (expense), net	651	2,098
Gains or losses		(399)
Net income	(7,525)	(23)
Balance for common		(23)
Earnings common share		
Primary	\$(1.26)	\$
Fully Diluted	\$(1.26)	\$
Common Shares:		
Full Diluted	5,966	3,757
Year-end	6,584	3,757

MONGODB INC

Earnings, 6 mos. to Jul 31(Consol. - \$000):

	2024	2023
Total Revenues	928,670	792,071
Net Sales		792,071
Cost & expenses	1,098,296	909,621
Operating income	(169,626)	(117,550)
Interest income		37,507
Interest expense		5,004
Other income (expense), net	(2,210)	(721)
Net before taxes	(128,644)	(85,768)
Income taxes	6,478	6,075
Net income	(135,122)	(91,843)
Balance for common		(91,843)
Earnings common share		
Primary	\$(1.84)	\$(1.30)
Fully Diluted	\$(1.84)	\$(1.30)
Common Shares:		
Full Diluted	73,270	70,532
Year-end	73,864	71,343

MOTORCAR PARTS OF AMERICA INC

Annual Report**Consolidated Income Statement, Years Ended Mar. 31 (\$000):**

	2024	2023	2022
Net sales	717,684	683,074	650,308
Cost of Goods Sold	585,133	569,112	532,443
Cost of goods sold	132,551	113,962	117,865
General & administrative expenses	54,756	57,499	57,499
Sales & marketing expenses	22,481	21,729	22,833
Research & development expenses	9,995	10,322	10,502
Foreign exchange impact of lease liabilities & forward contracts	3,814	9,291	1,673
General and administrative	57,769
Total operating expenses	86,431	77,516	89,161
Operating income (loss)	46,120	36,446	28,704
Interest expense, net	...	39,555	15,555
Interest, Net	(60,040)
Income before income taxes - United States	...	(14,470)	...
Income before income taxes - Foreign	...	11,361	...
Income (loss) before income tax expense (benefit)	(13,068)	(3,109)	13,149
Current income tax expense (benefit) - federal	1,696	2,483	8,572
Current income tax expense (benefit) - state	363	396	1,478
Current income tax expense - foreign	4,553	3,426	3,180
Total current income tax expense (benefit)	6,612	6,305	13,230
Deferred income tax expense (benefit) - federal	25,320	(5,037)	(6,411)
Deferred income tax expense (benefit) - state	4,249	(705)	(659)
Deferred income tax expense (benefit) - foreign	(5)	535	(372)
Total deferred income tax expense (benefit)	29,564	(5,207)	(7,442)
Income tax expense (benefit)	36,176	1,098	5,788
Income (loss) from continuing operations	(49,244)
Net income (loss)	(49,244)	(4,207)	7,361
Weighted average shares outstanding - basic	19,601	19,340	19,120
Weighted average shares outstanding - diluted	19,601	19,340	19,560
Year end shares outstanding	19,662	19,495	19,105
Income (loss) per share from continuing operations - basic	\$(2.51)
Net income (loss) per share - basic	\$(2.51)	\$(0.22)	\$0.38
Income (loss) per			

	2024	2023	2022
Net income (loss) per share - diluted	\$(2.51)	\$(0.22)	\$0.38
Number of full time employees	5,900
Total number of employees	5,900	5,600	5,800
Number of common stockholders	10	11	11
Foreign currency translation adjustments	...	4,763	2,630
Total Revenue	717,684
Change in fair value of compound net derivative liability	1,020
Loss on extinguishment of debt	(168)

□ Approximately; □ As is; □ As of June 7, 2022

Consolidated Balance Sheet, Years Ended Mar. 31 (\$000):

	2024	2023
Cash and cash equivalents	13,974	...
Cash & cash equivalents	...	11,596
Short-term investments	1,837	...
Short term investments	...	2,011
Accounts receivable - trade	118,500	136,076
Less: total accounts receivable offset	22,204	16,208
accounts	96,296	...
Accounts receivable - net	...	119,868
Accounts receivable - net	158,819	147,880
Raw materials	7,943	7,033
Work in process	227,650	201,198
Finished goods	...	16,436
Less allowance for excess & obsolete inventory	377,040	...
Inventory - net	20,288	16,579
Inventory unreturned	27,139	25,443
Contract assets	5,683	2,156
Income tax receivable	...	20,150
Prepaid expenses & other current assets	18,202	...
Prepaid expenses and other current assets	560,459	537,478
Total current assets	63,048	62,556
Machinery & equipment	33,463	32,769
Office equipment & fixtures	15,110	14,301
Leasehold improvements	111,621	109,626
Plant & equipment, gross	73,283	...
accumulated depreciation	...	63,574
Less accumulated depreciation	38,338	...
Plant and equipment - net	...	46,052
Plant & equipment - net	83,973	87,619
Operating lease assets	2,976	32,625
Deferred income taxes	320,282	318,381
Long-term contract assets	3,205	3,205
Goodwill	1,069	...
Intangible assets - net	...	2,143
Intangible assets - net	1,700	1,062
Other assets	1,012,002	1,028,565
Total assets	...	119,437
Accounts payable	30,205	22,329
Accrued liabilities	38,312	37,984
Customer finished goods returns accrual	...	40,340
Contract liabilities	...	145,200
Revolving loan	154,977	...
Accounts payable & accrued expenses	7,021	4,871
Other current liabilities
Operating lease liabilities	8,319	8,767
Current portion of term loan	...	3,664

Term loan - in default	128,000	...
Contract liabilities	37,591	...
Total current liabilities	404,425	382,592
Term loan before current portion	...	12,943
Term loan, less current portion	...	9,279
Less: current portion of term loan	...	3,664
Convertible notes, related party	30,776	30,994
Contract liabilities, less current portion	212,068	193,606
Deferred income taxes	511	718
Operating lease liabilities, less current portion	72,240	79,318
Other liabilities	6,872	11,583
Total liabilities	726,892	708,090
Common Stock	197	...
Common stock	...	195
Additional paid-in capital	236,255	231,836
Retained earnings	39,503	...
Retained earnings (accumulated deficit)	...	88,747
Foreign currency translation	9,155	...
Accumulated other comprehensive income (loss)	9,155	...
Accumulated other comprehensive income (loss)	...	(303)
Total shareholders' equity (deficit)	285,110	320,475
Total Equity	285,110	...

Recent Dividends:**1. Motorcar Parts of America Inc common.**

No dividends paid.

Annual Dividends:**1. Motorcar Parts of America Inc common.**

No dividends paid.

NASDAQ INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	3,469,000	2,966,000
Cost & expenses	2,328,000	2,038,000
Deprec., depl. & amort.	...	134,000
Operating income	833,000	794,000
Other income (expense), net	19,000	(4,000)
Net before taxes	653,000	732,000
Income taxes	198,000	165,000
Net income	455,000	567,000
Earnings common share		
Primary	\$0.79	\$1.16
Fully Diluted	\$0.79	\$1.15
Common Shares:		
Full Diluted	578,941	494,202
Year-end	576,064	491,275

NATIONAL CINEMEDIA INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/27/24	06/29/23
Total Revenues	92,100	49,700
Cost & expenses	103,000	76,600
Operating income	(32,000)	(35,500)
Other income (expense), net	(11,600)	(4,100)
Gains or losses	...	558,000
Net income	(43,400)	491,300
Earnings common share		
Primary	\$(0.45)	\$3.13
Fully Diluted	\$(0.45)	\$2.83
Common Shares:		
Full Diluted	96,664	173,491
Year-end	95,239	174,060

NETFLIX INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	18,929,750	16,348,804
Cost & expenses	13,694,379	12,807,304

	2024	2023
Total Revenues	1,782	3,618
Cost & expenses	87,033	48,215
Operating income	(85,251)	(44,597)
Other income (expense), net	80	424
Net before taxes	(84,248)	(43,173)
Income taxes	(1,718)	
Net income	(82,530)	(43,053)
Balance for common		(43,053)
Earnings common share		
Primary	\$(0.33)	\$(0.18)
Fully Diluted	\$(0.33)	\$(0.18)
Common Shares:		
Full Diluted	250,804	240,307
Year-end	252,656	255,483

PROGYNY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	582,165	537,767
Cost & expenses	542,955	507,572
Operating income	39,210	30,195
Other income (expense), net	6,924	1,775
Net before taxes	47,582	33,498
Income taxes	14,199	829
Net income	33,383	32,669
Earnings common share		
Primary	\$0.35	\$0.35
Fully Diluted	\$0.34	\$0.33
Common Shares:		
Full Diluted	99,456	100,392
Year-end	90,711	95,165

PYXIS ONCOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	16,146	
Cost & expenses	41,783	39,075
Operating income	(25,637)	(39,075)
Other income (expense), net	1,507	602
Net income	(20,557)	(35,144)
Earnings common share		
Primary	\$(0.37)	\$(0.95)
Fully Diluted	\$(0.37)	\$(0.95)
Common Shares:		
Full Diluted	55,892	36,879
Year-end	58,915	39,377

RACKSPACE TECHNOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	1,375,700	1,505,000
Cost & expenses	2,082,300	2,149,800
Operating income	(706,600)	(644,800)
Interest expense		114,200
Other income (expense), net	118,400	110,000
Invest. income	100	200
Net before taxes	(650,200)	(648,800)
Income taxes	(34,600)	(9,600)
Net income	(615,600)	(639,200)
Balance for common		(639,200)
Earnings common share		
Primary	\$(2.77)	\$(2.98)
Fully Diluted	\$(2.77)	\$(2.98)
Common Shares:		
Full Diluted	222,200	214,200
Year-end	225,600	215,700

RAMACO RESOURCES INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	327,991,000	303,829,000
Net Sales		303,829,000
Cost & expenses	288,204,000	236,509,000
Operating income	8,689,000	41,913,000
Other income (expense), net	3,151,000	3,742,000
Net before taxes	9,028,000	40,829,000
Income taxes	1,455,000	8,016,000
Net income	7,573,000	32,813,000
Earnings common share		
Primary	\$0.15	\$0.74
Fully Diluted	\$0.14	\$0.73
Common Shares:		
Full Diluted	53,033,000	44,949,315
Year-end	52,447,718	52,685,995

REDFIN CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	520,682	489,639
Cost & expenses	618,867	637,914
Operating income	(98,185)	(148,275)
Interest income		6,110
Interest expense		3,688
Other income (expense), net	11,585	61,974
Net before taxes	(94,267)	
Income taxes	387	643
Income contin. oper.		(84,522)
Net income	(94,654)	(88,156)
Balance for common	(95,078)	
Earnings common share		
Primary	\$(0.80)	\$(0.80)
Fully Diluted	\$(0.80)	\$(0.80)
Common Shares:		
Full Diluted	119,379	110,895
Year-end	121,744	113,935

RELMADA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Cost & expenses	41,806,644	54,180,335
Operating income	(41,806,644)	(54,180,335)
Interest income		2,571,037
Other income (expense), net		651,476
Gains or losses	5,248	(666,708)
Invest. income	186,247	
Net income	(39,596,248)	(51,624,530)
Earnings common share		
Primary	\$(1.31)	\$(1.72)
Fully Diluted	\$(1.31)	\$(1.72)
Common Shares:		
Full Diluted	30,153,186	30,099,203
Year-end	30,174,202	30,099,203

ROCKY BRANDS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	211,164,000	210,267,000
Net Sales		210,267,000
Cost & expenses	198,672,000	203,910,000
Operating income	12,492,000	6,357,000
Net before taxes	1,707,000	(3,937,000)
Income taxes	399,000	(823,000)
Net income	1,308,000	(3,114,000)
Balance for common		(3,114,000)
Earnings common share		
Primary	\$0.18	\$(0.42)
Fully Diluted	\$0.18	\$(0.42)
Common Shares:		
Full Diluted	7,466,000	7,350,000
Year-end	7,444,881	7,354,060

RUMBLE INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	40,202,999	42,589,429
Cost & expenses	108,030,752	99,383,702
Operating income	(73,818,114)	(58,518,907)
Other income (expense), net	(73,577)	(6,839,157)
Gains or losses	(723,695)	373,996
Net before taxes	(69,919,268)	(58,105,718)
Income taxes	151,472	16,475
Net income	(70,070,740)	(58,122,193)
Earnings common share		
Primary	\$(0.35)	\$(0.29)
Fully Diluted	\$(0.35)	\$(0.29)
Common Shares:		
Full Diluted	202,998,041	201,006,921
Year-end	283,168,891	385,923,761

SAB BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	1,207,712	666,619
Cost & expenses	22,800,026	14,545,246
Operating income	(21,592,314)	(13,878,627)
Other income (expense), net	842,962	(274,930)
Gains or losses	7,685,192	
Net income	(12,361,200)	(14,234,706)
Balance for common		(14,234,706)

Earnings common share

Primary	\$(1.34)	\$(2.80)
Fully Diluted	\$(1.34)	\$(2.80)
Common Shares:		
Full Diluted	9,248,503	5,040,741
Year-end	9,229,274	5,231,466

SANA BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Cost & expenses	160,096	200,341
Operating income	(160,096)	(200,341)
Interest income		4,350
Other income (expense), net	(3,906)	(131)
Net income	(157,766)	(196,122)
Balance for common		(196,122)
Earnings common share		
Primary	\$(0.70)	\$(1.02)
Fully Diluted	\$(0.70)	\$(1.02)
Common Shares:		
Full Diluted	225,872	191,888
Year-end	222,209	196,880

SCYNEXIS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	2,109	132,584
Net Sales		1,598
Cost & expenses	20,854	26,751
Operating income	(18,745)	105,833
Interest income		1,325
Other income (expense), net		(13,823)
Gains or losses	4,044	
Net before taxes	(13,524)	
Income taxes	523	
Net income	(14,047)	88,384
Balance for common		88,384
Earnings common share		
Primary	\$(0.29)	\$1.85
Fully Diluted	\$(0.29)	\$1.82
Common Shares:		
Full Diluted	48,379	49,166
Year-end	37,856	37,176

SIGHT SCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	40,635	42,296
Net Sales		42,296
Cost & expenses	68,010	75,050
Operating income	(27,375)	(32,754)
Interest expense		2,625
Other income (expense), net	(2,012)	3,580
Invest. income	3,174	
Net before taxes	(28,563)	(31,799)
Income taxes	32	22
Net income	(28,595)	(31,821)
Balance for common		(31,821)
Earnings common share		
Primary	\$(0.58)	\$(0.66)
Fully Diluted	\$(0.58)	\$(0.66)
Common Shares:		
Full Diluted	49,695	48,471
Year-end	50,136	48,649

SILGAN HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	2,698,403	2,845,008
Net Sales		2,845,008
Cost & expenses	2,444,831	2,569,787
Operating income	253,572	275,221
Net before taxes	173,582	191,663
Income taxes	42,321	40,744
Net income	131,261	150,919
Balance for common		150,919
Earnings common share		
Primary	\$1.23	\$1.37
Fully Diluted	\$1.23	\$1.36
Common Shares:		
Full Diluted	107,033	110,687
Year-end	106,779	109,946

SS&C TECHNOLOGIES HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	2,886,500	2,725,300
Cost & expenses	2,226,000	2,157,000
Operating income	660,500	568,300
Interest expense		229,900
Other income (expense), net	(2,000)	34,800
Net before taxes	429,200	373,200
Income taxes	80,500	116,100
Net income	348,700	257,100
Earnings common share		
Primary	\$1.41	\$1.03
Fully Diluted	\$1.38	\$1.00
Common Shares:		
Full Diluted	252,700	256,000
Year-end	244,800	248,000

STAR EQUITY HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	22,601,000	21,239,000
Net Sales		21,239,000
Cost & expenses	28,244,000	22,263,000
Operating income	(6,675,000)	(1,884,000)
Other income (expense), net	65,000	459,000
Net before taxes	(6,015,000)	(1,289,000)
Income taxes	(4,000)	61,000
Income contin. oper.		(1,350,000)
Net income	(6,011,000)	26,026,000
Balance for common	(6,969,000)	25,068,000
Earnings common share		
Primary	\$(1.90)	\$8.40
Fully Diluted	\$(1.90)	\$8.30
Common Shares:		
Full Diluted	3,170,000	3,141,200
Year-end	3,172,780	3,039,292

STOKE THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	9,048	2,671
Net Sales		2,671
Cost & expenses	66,762	60,624
Operating income	(57,714)	(57,953)
Interest expense		4,670
Other income (expense), net	(476)	84
Net income	(52,069)	(53,199)
Balance for common	(53,199)	(53,199)
Earnings common share		
Primary	\$(1.02)	\$(1.23)
Fully Diluted	\$(1.02)	\$(1.23)
Common Shares:		
Full Diluted	51,288	43,367
Year-end	52,306	44,203

SUPERIOR GROUP OF COMPANIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	270,578,000	259,935,000
Net Sales		259,935,000
Cost & expenses	262,008,000	257,614,000
Operating income	5,242,000	2,321,000
Net before taxes	5,242,000	2,321,000
Income taxes	730,000	220,000
Net income	4,512,000	2,101,000
Earnings common share		
Primary	\$0.28	\$0.13
Fully Diluted	\$0.27	\$0.13
Common Shares:		
Full Diluted	16,611,375	16,121,573
Year-end	16,792,577	16,499,312

SUTRO BIOPHARMA INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	38,714	23,086
Cost & expenses	143,990	111,502
Operating income	(105,276)	(88,416)
Interest income		5,402
Other income (expense), net	(5,983)	887
Net before taxes	(106,223)	(88,028)
Income taxes	8	546
Net income	(106,231)	(88,574)
Earnings common share		
Primary	\$(1.49)	\$(1.49)

	2024	2023
Fully Diluted	\$(1.49)	\$(1.49)
Common Shares:		
Full Diluted	71,341	59,536
Year-end	81,862	60,471

SYPRIS SOLUTIONS, INC.

Earnings, 6 mos. to (Consol. - \$000):

	06/30/24	07/02/23
Total Revenues	71,074	67,907
Net Sales		67,907
Cost & expenses	71,175	66,525
Operating income	(101)	1,382
Interest expense		404
Other income (expense), net	(535)	(584)
Net before taxes	(1,558)	394
Income taxes	647	356
Net income	(2,205)	38
Balance for common	(2,205)	37
Earnings common share		
Primary	\$(0.10)	\$.....
Fully Diluted	\$(0.10)	\$.....
Common Shares:		
Full Diluted	21,973	22,457
Year-end	23,024	22,415

T2 BIOSYSTEMS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	4,013	4,042
Cost & expenses	26,188	30,780
Operating income	(22,175)	(26,738)
Interest income		4
Interest expense		3,063
Other income (expense), net	357	5,485
Gains or losses	978	
Net income	(22,497)	(24,312)
Earnings common share		
Primary	\$(2.34)	\$(51.00)
Fully Diluted	\$(2.34)	\$(51.00)
Common Shares:		
Full Diluted	9,595	475
Year-end	17,394	2,418

TALKSPACE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	91,474,000	
Cost & expenses	96,639,000	84,428,000
Operating income	(5,165,000)	(15,447,000)
Net before taxes	(1,743,000)	(13,311,000)
Income taxes	197,000	151,000
Net income	(1,940,000)	(13,462,000)
Earnings common share		
Primary	\$(0.01)	\$(0.08)
Fully Diluted	\$(0.01)	\$(0.08)
Common Shares:		
Full Diluted	168,997,734	163,003,363
Year-end	168,169,158	166,204,295

TERNS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Cost & expenses	50,983	45,316
Operating income	(50,983)	(45,316)
Interest income		6,088
Other income (expense), net	(26)	(64)
Net before taxes	(44,951)	(39,292)
Income taxes	158	132
Net income	(45,109)	(39,424)
Earnings common share		
Primary	\$(0.61)	\$(0.56)
Fully Diluted	\$(0.61)	\$(0.56)
Common Shares:		
Full Diluted	74,430	70,576
Year-end	70,336	61,065

TRANSACT TECHNOLOGIES INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	22,286	42,176
Net Sales		42,176
Cost & expenses	24,025	37,139
Operating income	(1,739)	5,037
Other income (expense), net	(53)	21

Net before taxes	(1,718)	4,924
Income taxes	(363)	1,020
Net income	(1,355)	3,904
Balance for common		3,904
Earnings common share		

Primary	\$(0.14)	\$0.39
Fully Diluted	\$(0.14)	\$0.39
Common Shares:		
Full Diluted	9,985	10,016
Year-end	9,998	9,957

TREACE MEDICAL CONCEPTS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	95,563	84,148
Net Sales		84,148
Cost & expenses	135,913	110,976
Operating income	(40,350)	(26,828)
Interest income		3,670
Interest expense		2,567
Other income (expense), net	186	
Net income	(39,882)	(25,725)
Balance for common		(25,725)
Earnings common share		
Primary	\$(0.64)	\$(0.43)
Fully Diluted	\$(0.64)	\$(0.43)
Common Shares:		
Full Diluted	61,937	60,060
Year-end	62,175	61,528

TSCAN THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	1,102	9,951
Cost & expenses	66,589	57,304
Operating income	(65,487)	(47,353)
Interest income		2,670
Interest expense		1,925
Net income	(61,803)	(46,608)
Balance for common		(46,608)
Earnings common share		
Primary	\$(0.59)	\$(1.30)
Fully Diluted	\$(0.59)	\$(1.30)
Common Shares:		
Full Diluted	104,151	35,717
Year-end	52,933	47,819

UDEMY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2024	2023
Total Revenues	391,206	354,670
Cost & expenses	439,481	429,409
Operating income	(48,275)	(74,739)
Other income (expense), net	(10,892)	(2,303)
Net before taxes	(48,324)	(68,166)
Income taxes	1,829	2,113
Net income	(50,153)	(70,279)
Earnings common share		
Primary	\$(0.32)	\$(0.48)
Fully Diluted	\$(0.32)	\$(0.48)
Common Shares:		
Full Diluted	154,779	146,911
Year-end	151,682	149,846

ULTA BEAUTY INC

Earnings, 6 mos. to (Consol. - \$000):

	08/03/24	07/29/23
Total Revenues	5,277,935	5,164,072
Net Sales		5,164,072
Cost & expenses	4,547,786	4,330,360
Operating income	730,149	833,712
Net before taxes	741,575	845,509
Income taxes	175,906	198,356
Net income	565,669	647,153
Balance for common		647,153
Earnings common share		
Primary	\$11.83	\$12.97
Fully Diluted	\$11.78	\$12.90
Common Shares:		
Full Diluted	48,022	50,157
Year-end	47,300	49,341

UNITED-GUARDIAN, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2024	2023
Total Revenues	6,645,149	5,220,623
Net Sales	5,220,623	5,220,623
Cost & expenses	4,503,864	3,870,729
Operating income	2,141,285	1,349,894
Other income (expense), net	198,080	182,762
Gains or losses		
Invest. income	31,995	
Net before taxes	2,371,360	1,532,656
Income taxes		315,481
Net income	1,881,667	1,217,175
Balance for common		1,217,175
Earnings common share		
Primary	\$0.41	\$0.26
Fully Diluted	\$0.41	\$0.26
Common Shares:		
Full Diluted	4,594,319	4,594,319
Year-end	4,594,319	4,594,319

UNIVERSAL LOGISTICS HOLDINGS INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/29/24	07/01/23
Total Revenues	954,070	849,968
Cost & expenses	774,366	737,702
Deprec., depl. & amort.		37,675
Operating income	122,194	74,591
Interest income		1,373
Interest expense		11,469
Other income (expense), net	2,003	299
Net before taxes	111,235	64,794
Income taxes	28,044	16,352
Net income	83,191	48,442
Earnings common share		
Primary	\$3.16	\$1.84
Fully Diluted	\$3.16	\$1.84
Common Shares:		
Full Diluted	26,341	26,312
Year-end	26,317	26,288

UTAH MEDICAL PRODUCTS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	21,740,000	25,386,000
Net Sales		25,386,000
Cost & expenses	14,419,000	16,522,000
Operating income	7,321,000	8,864,000
Other income (expense), net	1,689,000	1,428,000
Net before taxes	9,010,000	10,292,000
Income taxes	1,601,000	1,878,000
Net income	7,409,000	8,414,000
Balance for common		8,414,000
Earnings common share		
Primary	\$2.07	\$2.32
Fully Diluted	\$2.07	\$2.31
Common Shares:		
Full Diluted	3,579,000	3,638,000
Year-end	3,499,000	3,629,000

VERINT SYSTEMS INC**Earnings, 6 mos. to Jul 31(Consol. - \$000):**

	2024	2023
Total Revenues	431,447	426,731
Cost & expenses	387,047	412,771
Operating income	38,315	1,260
Interest expense		5,385
Other income (expense), net	(923)	(173)
Foreign currency		173
Net before taxes	33,311	(335)
Income taxes	12,209	1,819
Net income	21,102	(2,154)
Balance for common	11,492	(13,105)
Earnings common share		
Primary	\$0.19	\$(0.20)
Fully Diluted	\$0.18	\$(0.20)
Common Shares:		
Full Diluted	62,732	64,603
Year-end	62,006	64,271

VERTEX PHARMACEUTICALS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	5,336,200	
Cost & expenses	7,711,400	3,062,600
Operating income	(2,375,200)	1,805,400

Interest income		267,300
Interest expense		22,600
Other income (expense), net	(54,300)	2,900
Net before taxes	(2,112,100)	2,053,000
Income taxes	381,900	437,500
Net income	(2,494,000)	1,615,500
Earnings common share		
Primary	\$(9.66)	\$6.27
Fully Diluted	\$(9.66)	\$6.21
Common Shares:		
Full Diluted	258,100	260,300
Year-end	258,015	257,793

VIDEO DISPLAY CORP**Earnings, 6 mos. to Aug 31(Consol. - \$000):**

	2024	2023
Total Revenues	3,404	3,831
Cost & expenses	3,754	4,030
Operating income	(350)	(199)
Other income (expense), net		524
Income contin. oper.		322
Net income	(350)	(96)
Earnings common share		
Primary	\$(0.06)	\$(0.02)
Fully Diluted	\$(0.06)	\$(0.02)
Common Shares:		
Full Diluted	5,878	5,878
Year-end	5,878	5,878

UYCOR MEDICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	743,246	685,285
Cost & expenses	706,839	685,285
Operating income	6,646	129,728
Other income (expense), net	4,544	
Foreign currency		(131)
Income contin. oper.	(40,496)	78,360
Net income	(40,646)	75,268
Balance for common	(202,831)	(86,917)
Earnings common share		
Primary	\$(0.01)	\$0.01
Fully Diluted	\$(0.01)	\$0.01
Common Shares:		
Full Diluted	32,628,835	37,415,572
Year-end	32,628,835	32,628,835

WD-40 CO**Earnings, 9 mos. to May 31(Consol. - \$000):**

	2024	2023
Total Revenues	434,566	396,803
Net Sales		396,803
Cost & expenses	361,459	329,561
Operating income	72,301	66,489
Interest income		164
Interest expense		4,268
Other income (expense), net		558
Net before taxes	68,725	62,943
Income taxes	15,865	13,525
Net income	52,860	49,418
Balance for common	52,671	49,211
Earnings common share		
Primary	\$3.89	\$3.62
Fully Diluted	\$3.88	\$3.62
Common Shares:		
Full Diluted	13,581	13,606
Year-end	13,548	13,568

WEYCO GROUP, INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2024	2023
Total Revenues	135,490,000	153,308,000
Net Sales		153,308,000
Cost & expenses	120,578,000	136,222,000
Operating income	14,912,000	17,086,000
Other income (expense), net	(238,000)	(298,000)
Net before taxes	16,543,000	16,600,000
Income taxes	4,286,000	4,291,000
Net income	12,257,000	12,309,000
Earnings common share		
Primary	\$1.30	\$1.30
Fully Diluted	\$1.28	\$1.28
Common Shares:		
Full Diluted	9,564,000	9,625,000
Year-end	9,490,681	9,520,864

WINMARK CORP**Earnings, 9 mos. to (Consol. - \$):**

	09/28/24	09/30/23
Total Revenues	61,741,100	63,203,600
Cost & expenses	21,576,700	22,441,900
Operating income	40,164,400	40,761,700
Interest expense		2,339,800
Net before taxes	38,856,300	39,225,300
Income taxes	8,485,100	8,764,000
Net income	30,371,200	30,461,300
Earnings common share		
Primary	\$8.65	\$8.77
Fully Diluted	\$8.29	\$8.40
Common Shares:		
Full Diluted	3,663,309	3,627,550
Year-end	3,520,402	3,486,869

XILIO THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2024	2023
Total Revenues	2,357	
Cost & expenses	34,548	43,642
Operating income	(32,191)	(43,642)
Other income (expense), net	1,063	1,641
Net income	(31,128)	(42,001)
Balance for common		(42,001)
Earnings common share		
Primary	\$(0.73)	\$(1.53)
Fully Diluted	\$(0.73)	\$(1.53)
Common Shares:		
Full Diluted	42,836	27,451
Year-end	43,952	27,519

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2024 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.